Telix Pharmaceuticals
Telix Pharmaceuticals Limited, commonly referred to as Telix, is a pioneering biopharmaceutical company headquartered in the United States, with significant operations across Europe and Asia-Pacific. Founded in 2015, Telix focuses on the development of innovative radiopharmaceuticals for the diagnosis and treatment of cancer, particularly in areas such as prostate and kidney cancers. The company’s core products, including its lead candidate TLX591 (also known as Illuccix), utilise advanced radiolabelled technologies that enhance precision in cancer imaging and therapy. Telix has established a strong market position, marked by notable achievements such as successful clinical trials and strategic partnerships that bolster its research and development capabilities. With a commitment to improving patient outcomes, Telix Pharmaceuticals is at the forefront of the evolving landscape of oncology therapeutics.
DitchCarbon Score
How does Telix Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Telix Pharmaceuticals's score of 15 is lower than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Telix Pharmaceuticals's reported carbon emissions
Telix Pharmaceuticals, headquartered in the US, currently does not have publicly available data regarding its carbon emissions, as no specific emissions figures have been reported. Additionally, there are no documented reduction targets or climate pledges outlined by the company. This lack of information suggests that Telix Pharmaceuticals may still be in the early stages of developing a comprehensive climate strategy or reporting framework. In the broader context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. As the industry evolves, it is likely that Telix Pharmaceuticals will align with these trends and establish measurable targets to address its carbon footprint in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Telix Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
